The Macrophage Activator GcMAF-RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming Full article
| Journal | Journal of immunology research ISSN: 2314-7156 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Output data | Year: 2024, Volume: 2024, Article number : 7484490, Pages count : DOI: 10.1155/2024/7484490 | ||||||||||
| Authors |  | ||||||||||
| Affiliations | 
 | 
                            Abstract:
                            Macrophages are the immune cells of high-immunological plasticity, which can exert both pro- and anti-inflammatory activity, as well as repolarize their phenotype to the opposite or neutral one. In this regard, M2 macrophages of the tumor-associated stroma (TAS) are a promising therapeutic target in treating malignant neoplasms. Using FACS assay, we have estimated the CD11b+/Ly-6G+/Ly-6C+ fraction of macrophages from the peritoneum and TAS in intact healthy mice and those with developed Lewis carcinoma, both untreated and treated according to Karanahan technology in combination with group-specific macrophage activator (GcMAF-RF). As well, the pattern of pro- and anti-inflammatory cytokines mRNA expression in different groups of experimental and tumor-bearing animals was assessed. It was found that: (i) exposure of intact mice to GcMAF-RF results in the increased number of CD11b+/Ly-6C+ peritoneal macrophages and, at the same time, the expression pattern of cytokines in peritoneal macrophages switches from that characteristic of the mixed M1/M2 phenotype to that characteristic of the neutral M0 one; (ii) combination of Karanahan technology and GcMAF-RF treatment results in M0/M1 repolarization of TAS macrophages; (iii) in tumor-bearing mice, the response of peritoneal macrophages to such a treatment is associated with the induction of anti-inflammatory reaction, which is opposite to that in TAS macrophages.
                        
                    
                
                        Cite:
                                Ruzanova V.S.
    ,        Kirikovich S.S.
    ,        Levites E.V.
    ,        Proskurina A.S.
    ,        Dolgova E.V.
    ,        Ritter G.S.
    ,        Efremov Y.R.
    ,        Dubatolova T.D.
    ,        Sysoev A.V.
    ,        Koleno D.I.
    ,        Ostanin A.A.
    ,        Chernykh E.R.
    ,        Bogachev S.S.
    
The Macrophage Activator GcMAF-RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming
Journal of immunology research. 2024. V.2024. 7484490 . DOI: 10.1155/2024/7484490 WOS Scopus OpenAlex
                    
                    
                                            The Macrophage Activator GcMAF-RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming
Journal of immunology research. 2024. V.2024. 7484490 . DOI: 10.1155/2024/7484490 WOS Scopus OpenAlex
                            Dates:
                            
                                                                    
                        
                    
                    | Submitted: | Jun 7, 2023 | 
| Accepted: | Feb 19, 2024 | 
| Published online: | Feb 29, 2024 | 
                        Identifiers:
                            
                    
                    
                                            
                    
                                            
                    
                | Web of science: | WOS:001180482400002 | 
| Scopus: | 2-s2.0-85187523661 | 
| OpenAlex: | W4392298341 |